2008 Top 10 Biopharmaceutical Companies Report
After years of producing this report, I’ve finally settled on definitive criteria for the Top Biopharma ranks! After consulting with Ronald A. Rader, president of the Biotechnology Information Institute, I decided that a Top Biopharma company is one that makes more than 40% of its drug revenues by selling biologic products, including biotherapeutics, vaccines and other proteins. No royalty-based companies allowed! (Sorry, ImClone.)
Unfortunately, this new criteria resulted in my only finding nine qualifying companies. I eventually settled on Elan for the tenth spot, since the company co-markets Tysabri with Biogen Idec. If you can think of other companies that qualify, drop me a line. (But don’t send me any small-molecule companies that call themselves biopharmas! That’s how I got into this mess!)
—Gil Y. Roth, Editor
| Top 10 Biopharmaceutical Companies |
||
| 01 | Amgen | $14,311 |
| 02 | Genentech | $9,443 |
| 03 | Novo Nordisk | $7,696 |
| 04 | Merck Serono | $6,111 |
| 05 | Baxter BioScience | $4,649 |
| 06 | Biogen Idec | $3,063 |
| 07 | Genzyme* | $2,764 |
| 08 | CSL Ltd.* | $2,327 |
| 09 | Allergan* | $1,212 |
| 10 | Elan* | $446 |
Based on 2007 biopharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
* PDF profiles only available for companies 7-10
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Novo Nordisk by Kristin Brooks
The Lowe Down capsules written by Derek Lowe
All pipeline information compiled by Kristin Brooks
Looking for the Top 20 Pharma companies report? Look no further!
